Program Awarded - Dr. Falk Pharma€¦ · General Information: FALK FOUNDATION e.V. Leinenweberstr....

General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49(0)761/1514-0Telefax: +49(0)761/1514-359E-mail: [email protected]

P192

e 1-

05/2

014

/1.3

00

Stü

Program

Falk Symposium 192

IBD 2014:Thinking Out of the Box

May 30 – 31, 2014Le Palais des Congrès de ParisParis, France

CME credits 11

Awarded with

110975_Falk_Paris_Symp192_Prog_UG.indd 1 08.05.14 09:41

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

List of Speakers, Moderators and Scientific Organizers . . . . . . . . . . . . . . . . . . . . . . . . 22

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

11 credit hours (CME) have been awarded for the Falk Symposium 192 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG) .

110975_Falk_Paris_Symp192_Prog_Inhalt.indd 3 08.05.14 14:45

4

Preface

Dear Colleagues,

Significant scientific progress has been made in recent years in the etiopathogenesis of inflammatory bowel diseases (IBD) that has changed or will shortly change the current management of IBD .

The relevance of well-established IBD therapies has been critically re-evaluated under criteria of evidence-based medicine approaches and new therapeutic strategies have emerged . New therapeutic options are assessed in an increasing number of clinical trials and include alternative immunomodulatory approaches, biologics, probiotics, worm eggs, lecithins, cell-based therapies and others . The clinical relevance of these new modalities is still difficult to assess, as physicians have only limited experience with these modalities beyond clinical trials, where patients are highly selected and do often not represent the general IBD population . The availability of more treatment options results in even more different treatment algorithms including various sequences of medical or surgical approaches .

This symposium aims to critically discuss established and emerging new concepts in the management of IBD reflecting the recent advancements . Controversial problems, emerging new treatment options, new therapeutic strategies and a view outside our current pathways and look across our own horizon will be addressed . Difficult therapeutic situations will be critically analyzed and discussed . The program is designed to provide opportunities for discussion, and a lively interaction between the speakers, moderators and the audience is expected .

Axel Dignass

Chairman of the Scientific Committee


5

Registration:Thursday, May 29, 201416 .00 – 21 .00 hat the congress office

Scientific Organization:M . Allez, Paris (France)S . Danese, Rozzano (Italy)A . Dignass, Frankfurt (Germany)P . Marteau, Paris (France)

Congress Venue:Le Palais des Congrès de Paris2 Place de la Porte Maillot75853 Paris Cedex 1France

Information:Prof . Dr . Axel DignassInnere Medizin IAgaplesion Markus KrankenhausWilhelm-Epstein-Str . 460431 FrankfurtGermanyTelephone: +49 (0)69/9533-2201Telefax: +49 (0)69/9533-2291E-Mail: axel .dignass@fdk .info

Official Language:English . Simultaneous translation into French .

Posters:For details see page 10 .

Falk Symposium 192




6

Friday, May 30, 2014

9.00 Welcome A . Dignass, Frankfurt

Session I Environment and the flora in IBD: Partners in crime?

Chair: W . Kruis, Cologne; P . Marteau, Paris

9.10 What have we learnt about the role of environment B . Moum, and natural course of IBD in the new millennium? Oslo 20 year follow-up of the IBSEN Cohort

9.30 Probiotics and Antibiotics H . Sokol, Paris

9.50 Fecal transplantation in IBD J . Raes, Brussels

10.10 Flora manipulation through diet and modified J . M . Rhodes, bacteria Liverpool

10.30 Coffee break with poster session

Session II Fibrosis in IBD

Chair: P . L . Lakatos, Budapest; G . Rogler, Zurich

11.00 Mechanisms and models for intestinal fibrosis T . Torres Pizarro, Cleveland

11.20 Clinical Management of intestinal stenosis: G . van Assche, Pro: Conservative endoscopic and medical treatment Leuven

11.40 Clinical Management of intestinal stenosis: A . D’Hoore, Pro: Surgical treatment Leuven

12.00 New therapeutic avenues for treatment of fibrosis: G . Rogler, Can we learn from other diseases? Zurich

12.20 Lunch break with poster session


7

Friday, May 30, 2014

Session III Cell-based therapies

Chair: J . Panés, Barcelona; W . Reinisch, Vienna

14.00 Cardiac Stem cell transplantation – A . M . Zeiher, What can we learn from the cardiologist? Frankfurt

14.20 Hematopoietic stem cell transplantation M . Allez, for Crohn‘s disease Paris

14.50 Mesenchymal stem cell transplantation L . Egan, Galway

15.10 Cell based therapy for IBD J .-F . Colombel, New York


Special Lecture Chair: M . Allez, Paris; A . Dignass, Frankfurt

16.00 Cytokines for IBD: Past, present and future S . Schreiber, Kiel

Session IV New therapies or new therapeutic strategies in IBD?

Chair: B . Siegmund, Berlin; C . J . van der Woude, Rotterdam

16.30 Trichuris suis ova, lecithin and other fancy molecules J . Schölmerich, Frankfurt

16.50 New drugs on the horizon for IBD B . E . Sands, New York

17.10 Treat the lesions or treat the symptoms? G . D’Haens, New treatment algorithms Amsterdam

17.30 The clinical studies that should be performed in IBD J . Panés, Barcelona

17.50 End of afternoon session


8

Saturday, May 31, 2014 Session V

Best use of biologics in 2014 Chair: Y . Bouhnik, Clichy; F . J . Magro Dias, Porto

9.00 Starting and stopping anti-TNF drugs R . Panaccione, Calgary

9.20 Can anti-TNF therapy change the course of disease? A . Sturm, Berlin

9.40 Biosimilars: Are they bioequivalent? F . Gomollón, Zaragoza

10.00 Tailoring treatment to the individual patient: W . J . Sandborn, Drug monitoring La Jolla


Session VI Current role of immunosuppressants in IBD

Chair: L . Beaugerie, Paris; H . Tilg, Innsbruck

10.50 Optimal treatment of early CD and UC E . Louis, Liège

11.10 Treatment of established CD and UC – J . Cosnes, Still a role for Aza Paris

11.30 Special situations: Perianal disease and S . Ghosh, postoperative period Calgary

Special Lecture Chair: A . Dignass, Frankfurt; P . Marteau, Paris

11.50 Integrating omics: The future in IBD? C . Fiocchi, Cleveland

12.20 Lunch break with poster session


9

Saturday, May 31, 2014 Session VII

The complicated IBD patient: Clinical case marathon

Chair: W . A . Bemelman, Amsterdam; L . Peyrin-Biroulet, Nancy

13.20 Presentation of Poster Prizes A . Dignass, Frankfurt

13.30 Tandem talk: A patient with Crohn’s disease and F . Carbonnel, intra-abdominal infection (abscess): The place and Le Kremlin Bicetre timing of biologics and surgery W . A . Bemelman, Amsterdam13.55 Tandem Talk: Refractory distal ulcerative colitis – Is proctocolectomy always necessary?

Pro: Proctocolectomy A . Spinelli, Rozzano

Con: Proctocolectomy E . F . Stange, Stuttgart

14.20 Previous cancer and/or lymphoma in patients with refractory IBD:

Pro: Anti-TNF or immunosuppressive treatment D . Laharie, Pessac

Con: Anti-TNF or conventional immunosuppressive G . Mantzaris, treatment Athens

14.45 Refractory pouchitis: Probiotics, immunosuppressive I . Dotan, therapy or pouch removal? Tel Aviv

15.10 Closing Remarks P . Marteau, Paris

15.20 End of afternoon session


10

Poster SessionPosters will be exhibited on May 30-31, 2014 at Le Palais des Congrès de Paris . The authors will be in attendance during coffee and lunch breaks on both days .

1 . Intestinal anti-inflammatory effects of Lavandula dentata and Lavandula stoechas extracts in the TNBS model of rat colitis F . Algieri, A . Rodriguez-Nogales, T . Vezza, J . Garrido-Mesa, N . Garrido-Mesa, M .P . Utrilla, O . Banuelos, M .R . Gonzales-Tejero, M . Casares-Porcel, J . Molero-Mesa, A . Zarzuelo, M .E . Rodriguez-Cabezas, J . Galvez (Granada, ES)

2 . Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation A . Assa, L . Vong, L . Pinnell, N . Avitzur, K .C . Johnson-Henry, P .M . Sherman (Toronto, CA)

3 . The association of antiglycan antibodies with abdominal operation requirement in patients with stenosing Crohn‘s disease A .E . Atay, E . Yorulmaz, G . Adali, G . Tasan, I . Tuncer (Istanbul, TR)

4 . STAT3 activation in CD4+ lymphocytes shapes epithelial host defense during infectious colitis I . Backert, S .B . Koralov, S . Wirtz, K . Hildner, M .F . Neurath, C . Becker, C . Neufert (Erlangen, DE; New York, US)

5 . Anemia can add morbidity in inflammatory bowel disease D . Badea, M . Badea, A . Genunche, C . Petrica, A . Badea, D . Duta, D . Iordache (Craiova, RO)

6 . What staging system is better in the gastrointestinal lymphoma? M . Badea, D . Badea, A . Genunche, A . Badea, D . Iordache, L . Stefan, D . Duta (Craiova, RO)

7 . Probiotics lactobacillus and bifidobacterium prevent the occurrence of pouchitis and decrease his severity in long-term therapy – Randomized prospective study T . Banasiewicz, J . Walkowiak, J . Szmeja, R . Marciniak, M . Grochowalski, M . Drews (Poznan, PL)

8 . Macroscopic findings in microscopic (collagenous) collitis; an update from Edinburgh L . Bartzis, M . MacNeill, P . Fineron, A . Koulaouzidis (Edinburgh, GB)

9 . Serum endocan levels in inflammatory bowel disease Ö . Basar, O . Yüksel, T . Pürnak, S . Koklu (Ankara, TR)

10 . The prevalence of liver, biliary tract and pancreas abnormalities in patients with inflammatory bowel disease screened by US: Not frequent, but also not rare M . Basaranoglu, M . Yüksel, A . Demirbag, S . Kacar, C . Karacaer, Y . Ozin, M . Yalinkilic, E . Kayacetin (Ankara, TR)


11

11 . Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis may increase prevalence of PSC with dominant stricture in a short period like 24 months M . Basaranoglu, M . Yüksel, N . Turhan, G . Nesser, A . Demirbag (Ankara, TR)

12 .* Can we predict response to cyclosporine as second line therapy in patients with severe acute colitits of inflammatory bowel disease? N . Ben Mustapha, A . Laabidi, M . Serghini, H . Dabbabi, M . Fekih, J . Boubaker, A . Filali (Tunis, TN)

13 . Cardiac rhythm perturbations in young patients with inflammatory bowel diseases M .C . Bezna, C . Deliu, A . Coltescu (Craiova, RO)

14 . Ulcerative colitis associated with overlap syndrome by multiple immune perturbations M . Bezna, M . Bezna, C . Deliu, S . Bezna, A . Coltescu (Craiova, RO)

15 . Newly diagnosed synchronized CMV colitis and ulcerative colitis: A case report Ö .B . Binicier, Z .B . Paköz, I .S . Ertem, C . Yildiz, F .M . Alanyali, B . Geroglu (Izmir, TR)

16 . Leukocyte scintigraphy as a tool to measure inflammatory load in ulcerative colitis J .F . Brandse, R .J . Bennink, S . van Eeden, P .A . Baars, M . Löwenberg, C .Y . Ponsioen, G .R . van den Brink, G . D‘Haens (Amsterdam, NL)

17 . Crohn‘s disease in adolescent females presented by perivulvar disease E . Broide, R . Castiel-Levinson, R . Shamir, H . Shirin, A . Padowa (Zerifin, Petach Tikva, IL)

18 . A single viral protein is able to disrupt intestinal immune homeostasis in vivo B . Buchen, C . Günther, M . Stürzl, E . Cesarman, G . Ballon, M .F . Neurath, C . Becker (Erlangen, DE; New York, US)

19 . Diagnostic utility of „gastrointestinal wall thickening“ for the diagnosis of IBD in children M . Cakir (Trabzon, TR)

20 . Early onset (< 5 years old) IBD in Turkish children M . Cakir, F . Ünal, G . Dinler, M . Baran, H .A . Yüksekkaya, G . Tümgör, E . Kasirga, A .G . Kalayci, S . Aydogdu (Trabzon, Bursa, Samsun, Konya, Adana, Manisa, Izmir, TR)

21 . Incidence of low bone mineral density and affecting factors in inflammatory bowel disease H . Can, F . Akbay Harmandar, A .H . Cekin, V . Yilmaz Taskin, A . Duman, F .Y . Adakan, B . Yesil (Antalya, TR)

22 . Clinical risk factors for underlying gastrointestinal malignancy in iron deficiency anaemia . Iron Deficiency as an Indicator Of Malignancy – The IDIOM study A . Castro Silva, Z .A . Sheppard, S .L . Surgenor, E .J . Williams, P .W . Thomas, J .A . Snook (Bournemouth, Poole, Dorset, GB)

23 . Malnutrition – Left out of the box? I . Chermesh, T . Mashiach, Y . Chowers (Haifa, IL)

24 . Can we predict disease relapse in patients with inflammatory bowel disease? G . Chiriac, I . Copaci (Bucharest, RO)


12

25 . Polypharmacy and adverse events to therapy in IBD patients – An analysis of the AGED study (IG-IBD) M . Cintolo, A . Viola, M . Coppola, D . Pugliese, A . Ferrara, S . Saibeni, G . Mocci, F . Castiglione, F . Calella, F . Furfaro, C . Papi, V . Annese, F . Bossa, F . Manguso, W . Fries (Messina, Florence, Rome, Milan, Cagliari, Empoli, San Giovanni Rotondo, Naples, IT)

26 . A case report of the first pediatric patient treated with anti-TNFα in Romania and the long-term disease course A . Constantinescu, G . Duica, R . Vadan, L . Gheorghe, C . Gheorghe (Bucharest, RO)

27 . Mucosal healing in IBD: De-escalation therapy or maintenance therapeutic approach in patients achieving mucosal healing G . Constantino, L . Amato, A . Sitibondo, A . Alibrandi, W . Fries (Messina, IT)

28 . Fast safe and effective treatment of iron deficiency (ID) of different aetiologies using iron isomaltoside 1000 – Experience from clinical pratice L . Craven, S . Surgenor, J . Snook, E . Williams (Poole, Dorset, GB)

29 . Fibrosis does not increase with disease duration in ulcerative colitis J . de Bruyn, S . Meijer, M . Wildenberg, W . Bemelman, G . van den Brink, G . D‘Haens (Amsterdam, NL)

30 . Normalization of alkaline phosphatase within the first year after diagnosis is of prognostic value in primary sclerosing cholangitis E . de Vries, K . Boonstra, M . Leeflang, U . Beuers, C .Y . Ponsioen (Amsterdam, NL)

31 . Comparative efficacies of novel JAK inhibitors to reduce macrophage activation L .C .S . de Vries, J .M . Duarte, F .W .M . Hilbers, V .J . Ludbrook, M .D . Woodrow, M .J . Sims, M . de Winther, P .D . Moerland, G . D‘Haens, W .J . De Jonge (Amsterdam, NL; Stevenage, GB)

32 . Risk factors and frequency of extraintestinal manifestations in inflammatory bowel disease C . Deliu, D . Neagoe, C . Bezna (Craiova, RO)

33 . Inflammatory bowel disease – The frequency of low bone mineral density C . Deliu, D . Neagoe, C . Bezna (Craiova, RO)

34 . Mucosal and systemic immune modulation from Trichuris trichiura in a slef-infected individual A . Dige, T . Rasmussen, P . Nejsum, R . Hagemann-Madsen, J . Agnholt, J . Dahlerup, C . Hvas (Aarhus, Copenhagen, Vejle, DK)

35 . The short inflammatory bowel disease questionnaire (SIBDQ) is a good predictor of mucosal healing in patients with ulcerative colitis and Crohn‘s disease R . Dinu, T . Voiosu, A . Bengus, B . Mateescu (Bucharest, RO)

36 .* Intestinal epithelial IL-28 signaling via STAT-1 but not STAT-2 links mucosal wound healing H . Dornhoff, K . Fietkau, S .E . Doyle, J . Siebler, M .F . Neurath (Erlangen, DE; Seattle, US)


13

37 . Correlation between endoscopic and histological disease activity in ulcerative colitis and Crohn‘s disease S . Dragasevic, A . Sokic-Milutinovic, S . Lukic, T . Alempijevic, T . Milosavljevic, D . Popovic (Belgrade, RS)

38 . Case report of a family with 10 members with hepatits B infection – Evolutions over a decade of time R . Dumitru, A . Constantinescu (Bucharest, RO)

39 . Granulomatous gastritis in Crohn‘s disease E . Ergin, D . Demir (Manisa, TR)

40 . Optimizing anti-TNFα therapy in IBD: Monitoring of trough levels and anti-drug antibodies P . Esters, H . Schulze, J . Thieringer, J . Stein, A . Dignaß (Frankfurt, DE)

41 . Long-term outcome of patients with steroid-treated ulcerative colitis: A retrospective comparative study M . Fekih, A . Laabidi, N . Ben Mustapha, Y . Kardouss, M . Serghini, L . Kallel, S . Matri, J . Boubaker, A . Filali (Tunis, TN)

42 . Epidemiology of bowel cancer in inflammatory bowel disease patients: A monocenter study A . Filali, N . Ben Mustapha, A . Laabidi, M . Serghini, L . Kallel, M . Fekih, J . Boubaker (Tunis, TN)

43 . Interleukin 22 and interleukin 23R gene expression in Crohn‘s disease: Preliminary results A . Filali, S . Matri, M . Bejaoui, M . Serghini, N . Ben Mustapha, M . Fekih, J . Boubaker (Tunis, TN)

44 . Ulcerative colitis (UC) in the elderly – Moderate at onset but then a milder course? The AGED IG-IBD study W . Fries, A . Viola, N . Manetti, M . Coppola, I . Frankovic, R . Monterubbianesi, D . Pugliese, A . Aratri, M . Cappello, S . Saibeni, M . Principi, P . Naccarato, G . Mocci, F . Castiglione, F . Calella, A . Magarotto, F . Caprioli, A . Belvedere, G . Casella, L . Samperi, A .C . Privitera, G . Inserra, S . Danese, C . Papi, A . Armuzzi, A . Kohn, R . D‘Inca, V . Annese, F . Manguso (Messina, Florence, Padua, Rome, Palermo, Milan, Bari, Rozzano, Cagliari, Naples, Empoli, Desia, Catania, IT)

45 . The inhibition of IkB kinase ameliorates experimental colitis in rats J . Galvez, F . Algieri, A . Rodriguez-Nogales, J . Garrido-Mesa, P . Utrilla, J . Chen, M .E . Rodriguez-Cabezas, C . Thiemermann (Granada, ES; London, GB)

46 . Novel markers to evaluate immunomodulatory effects of antibiotics in DSS-colitis: Micro-RNA expression and microbiota populations J . Garrido-Mesa, A . Rodriguez-Nogales, F . Algieri, N . Garrido-Mesa, P . Utrilla, M .E . Rodriguez-Cabezas, F . Garcia, N . Chueca, J . Galvez (Granada, ES)


14

47 . Beneficial effects of the association of Saccharomyces boulardii and doxycycline in an experimental model of reactivated colitis in mice N . Garrido-Mesa, J . Garrido-Mesa, A . Rodriguez-Nogales, F . Algieri, P . Utrilla, M .E . Rodriguez-Cabezas, J . Galvez (Granada, ES)

48 . Differentially expressed serum protein markers among adults and children Crohn‘s disease patients M . Gazouli, A . Vaiopoulou, A . Papadopoulou, A .K . Anagnostopoulos, G . Karamanolis, G .E . Theodoropoulos, G .T . Tsangaris (Athens, GR)

49 . The first-line therapy with azathioprine as alternative for the induction of remission in elderly and steroid-refractory patients with UC A . Genunche-Dumitrescu, D . Badea, M . Badea, P . Mitrut, A . Badea (Craiova, RO)

50 . Comparison of efficacy and tolerance of usual therapies in the treatment of severe steroid-refractory Crohn‘s disease A . Genunche-Dumitrescu, D . Badea, M . Badea, P . Mitrut, A . Badea (Craiova, RO)

51 .* PU .1 expressing Th9 cells drive T-cell mediated ulcerative colitis K . Gerlach, A . Nikolaev, R . Atreya, S . Wirtz, M .F . Neurath, B . Weigmann (Erlangen, Mainz, DE)

52 . Five-year follow of a self-management programme for patients with inflammatory bowel disease S . Gethins, B . Robinson, T . Duckett, R . Robinson (Leicester, GB)

53 . Effects of C-reactive protein (CRP) gene polymorphism in inflammatory bowel diseases F .D . Gunsen, N . Oruc, C . Aktan, O . Ozutemiz, N . Osmanoglu (Izmir, TR)

54 . Intestinal epithelial caspase-8 differentially regulates the gut response to IFN receptor signaling in vivo C . Günther, B . Buchen, H . Neumann, M .F . Neurath, C . Becker (Erlangen, DE)

55 . The role of short-chain fatty acids in angiogenesis A . Hamad, R .M . Day, A . Forbes, A . Burns (London, GB)

56 . Uncommon cancer as a complication of ulcerative colitis A . von Herbay, S . Keshav, J . Stern (Heidelberg, Hamburg, DE; Oxford, GB; Dortmund, DE)

57 .* Top-down versus step-up treatment in newly diagnosed Crohn‘s disease: No difference in long-term outcome D .R . Hoekman, J .A . Stibbe, F .J . Baert, P . Caenepeel, P . Vergauwe, M . de Vos, S . Vermeire, G . D‘Haens (Amsterdam, NL; Roeselare, Leuven, Kortrijk, Gent, BE)

58 . Management of the inflammation in patients with IBD and chronic vein disease G . Iliescu, V . Biciusca, A . Bold, A . Buteica, D . Visan (Craiova, RO)

59 . Minor problem – major issue in the life of the patients with Crohn‘s disease: The hair loss G . Iliescu, M . Jifcu, V . Biciusca, A . Bold, A . Buteica, D . Visan (Craiova, RO)


15

60 . Parenchymal changes of the pancreas in patients with IBD was not frequent among the patients with chronic pancreatitis S . Kacar, M . Basaranoglu, Y . Ozin, M . Yalinkilic (Ankara, TR)

61 . Severe colitis related to granulomatosis with polyangiitis (Wegener‘s) F . Karaahmet, S . Kilincalp, Y . Coskun, S . Coban, I . Yuksel (Ankara, TR)

62 . Micro-RNAs as possible diagnositic biomarkers in inflammatory bowel disease G . Karamanolis, M . Gazouli, I . Papakonstantinou, C . Tzathas (Athens, GR)

63 . Transepithelial transport of E .coli LF82 is inhibited by blocking of the receptor CEACAM-6 in the follicle-associated epithelium of patients with ileal Crohn‘s disease A .V . Keita, O . Yakymenko, B . Chassaing, A . Darfeuille-Michaud, J .D . Söderholm (Linköping, SE; Clermont-Ferrand, FR)

64 . Atypical pANCA as a marker of indeterminate colitis for the prediction of ulcerative colitis and Crohn‘s disease M . Kekilli, Y . Beyazit, A . Tas, B . Tunc (Ankara, Canakkale, Corum, TR)

65 . Polymorphisms of interleukin-23 receptor in patients with inflammatory bowel disease in a Croatian Tertiary Center A . Kibel, S . Mihaljevic, M . Stefanic, L . Glavas-Obrovac, Z . Krznaric, B . Takac, I . Segec (Osijek, Zagreb, HR)

66 . The interchangeability of monoclonal antibodies of tumor necrosis factor-α, infliximab and CT-P13, in safety and efficacy J .H . Kim, K .H . Hong (Goyang, KR)

67 . Comparison of IBD treatment in dependence on the age of patients M . Konecny (Olomouc, CZ)

68 . Lewis score in small-bowel capsule endoscopy and correlation with faecal cal-protectin; as good as it gets? A . Koulaouzidis, A . Nemeth, G . Wurm Johansson, E . Toth (Edinburgh, GB; Malmö, SE)

69 . Protective and anti-inflammatory effects of ursodeoxycholic acid in colonic epithelia N .K . Lajczak, V . Saint-Criq, M .S . Mroz, S .J . Keely (Dublin, IE)

70 . C . rodentium exploits T6SS (Type 6 Secretion System) to create gut dysbiosis R . Lakra, M .F . Neurath, C . Riedel, S . Wirtz (Erlangen, Ulm, DE)

71 . Association of DNA methylation profile of genes involved in inflammation and autophagy with the response of Crohn‘s disease patients to infliximab E . Legaki, P . Karatzas, G . Mantzaris, K . Papamichael, N .P . Anagnou, M . Gazouli (Athens, GR)

72 . Rho-dependent cytoskeleton rearrangement due to lack of geranylgeranylation within intestinal epithelial cells (IECs) leads to breakdown of intestinal homeostasis R . López-Posadas, M .O . Bergo, C . Becker, K . Amann, S . Tenzer, R . Atreya, M .F . Neurath, I . Atreya (Erlangen, Mainz, DE; Gothenburg, SE)


16

73 . The viability of Lactobacillus fermentum CECT5716 is not required to exert its intestinal anti-inflammatory activity M .D . Lorente, A . Rodriguez-Nogales, F . Algieri, T . Vezza, N . Garrido-Mesa, A . Zarzuelo, M . Olivares, M . Comalada, M .E . Rodriguez-Cabezas, J . Galvez (Granada, Barcelona, ES)

74 . The polymorphisms of the CARD15/NOD2 gene: Relation to the phenotype and the association with familial cancer anamnesis in the Ukrainian inflammatory bowel disease patients M . Lozynska, A . Plawski, L . Lozynska (Lviv, UA; Poznan, PL)

75 . Interleukin-33 promotes intestinal barrier function by direct effects on epithelial proliferation and differentiation M . Mahapatro, G . He, C . Günther, M .F . Neurath, S . Wirtz, C . Becker (Erlangen, DE)

76 . Co-medication in inflammatory bowel disease patients – Results from tertiary IBD center M . Majerovic, M . Crncevic Urek, M . Brinar, N . Turk, S . Cukovic-Cavka, Z . Krznaric, B . Vucelic (Zagreb, HR)

77 . Dynamics of endoscopic activity index of ulcerative colitis during treatment with mesalazine P . Makarchuk (Moscow, RU)

78 . Effects of aerobic exercise on tumor growth in colitis-associated cancer T . Marini-Menezes, S .B . Garcia, J .G . Menezes, S . Wirtz, M .F . Neurath, M . Waldner (Erlangen, DE; Ribeirao Preto, BR)

79 . Predictive factors of favorable response to first-line therapy of severe acute colitis in inflammatory bowel disease patients S . Matri, A . Laabidi, N . Ben Mustapha, M . Serghini, M . Fekih, J . Boubaker, A . Filali (Tunis, TN)

80 . Long-term efficacy of adalimumab therapy in Crohn‘s disease L . Milatchkov, D . Panova, Z . Spassova, R . Nikolov (Sofia, BG)

81 . Potential of one-step card tests for fecal calprotectin and fecal lactoferrin in evaluation of IBD patients L . Milatchkov, T . Velikova, Z . Spassova, E . Ivanova-Todorova, D . Kyurkchiev, R . Nikolov, I . Altankova (Sofia, BG)

82 . Analysis of adenomas related with inflammatory bowel diseases V . Mokricka, A . Pukitis (Riga, LV)

83 . Autologous hematopoietic stem cell transplantation in two pediatric patients with refractory Crohn‘s disease K . Müller, G . Krivan, K . Kallay, D . Szabo, L . Kovacs, D . Krikovszky, G . Veres (Budapest, HU)


17

84 . Patient and professionals perceptions of travel behaviour in inflammatory bowel disease J .-P . Mulligan, K . Greveson, T .C . Shepherd, M .I . Hamilton, C .D . Murray (London, GB)

85 .* Screening for opportunistic infection prior to commencing immunomodulator therapy in IBD patients – Practice in the North East of England S . Nair, D . Hobday (Sunderland, GB)

86 . Main mechanism for anemia in inflammatory bowel disease D . Neagoe, G . Ianosi, L . Simion, V . Toma, A . Genunche-Dumitrescu, C . Deliu, T . Ciurea (Craiova, RO)

87 . Bile acids attenuate IL-8 release from U937 monocytes A . O‘Dwyer, J . Ward, S . Keely (Dublin, IE)

88 . Correlation of serum biomarkers, Mayo endoscopic score and UCEIS in patients with ulcerative colitis A . Ocepek, G . Vujnovic, C . Pernat Drobez (Maribor, SI)

89 . Inflammatory and cancerous skin lesions in inflammatory bowel disease patients treated with anti-TNF therapy A . Ocepek, C . Pernat Drobez (Maribor, SI)

90 . Fecal calprotectin and serum neutrophil gelatinase-associated lipocalin (NGAL) in the diagnosis of inflammatory bowel disease in children A . Ochocinska, R . Snitko, J . Kierkus, M . Meglicka, R .M . Janas (Warsaw, PL)

91 . Clinic characteristics of ulcerative colitis associated with autoimmune pancreatitis N . Oruc, G . Ersoz, O . Ozutemiz (Izmir, TR)

92 . The IL-6 gene polymorphism at -174 C>G in the association with ulcerative colitis and Crohn‘s disease I . Ozola Zalite, L . Zepa, V . Mokricka, M . Leja, L . Niktina Zake, A . Pukitis (Riga, LV)

93 . Polymorphisms of survivin promoter and Crohn‘s disease I . Papaconstantinou, E . Legaki, E . Rapti, M . Gazouli, G . Karamanolis (Athens, GR)

94 .* Prediction of sustained clinical remission after discontinuation of infliximab in patients with Crohn‘s disease K . Papamichail, N . Vande Casteele, S . Hauenstein, F . Princen, S . Singh, M . Ferrante, G . Van Assche, P . Rutgeerts, A . Gils, S . Vermeire (Athens, GR; Leuven, BG; San Diego, US)

95 . Are factors of fibrosis YKL-40 and PIIINP are useful in pediatric inflammatory bowel diseases? S . Pieczarkowski, P . Tomasik, P . Kwinta, A . Wedrychowicz, K . Kowalska-Duplaga, Z . Grzenda, M . Sladek, K . Fyderek (Cracow, PL)

96 . A meta-analysis on IL-12 and IL-23 in the pathogenesis of inflammatory bowel disease T . Purnak, Y . Beyazit, M . Kekilli (Ankara, TR)


18

97 . Evaluation of resveratrol loaded silk fibroin nanoparticles in an experimental model of rat colitis M .E . Rodriguez-Cabezas, A .A . Lozano-Perez, A . Rodriguez-Nogales, V . Ortiz, F . Algieri, J . Garrido-Mesa, N . Garrido-Mesa, M .P . Utrilla, L . Matteis, J . Martinez de la Fuente, J .L . Cenis, J . Galvez (Granada, Murcia, Zaragoza, ES)

98 . Immunomudulatory properties of probiotics in DSS colitits: Impact on microRNA expression and bacterial diversity A . Rodriguez-Nogales, J . Garrido-Mesa, F . Algieri, N . Garrido-Mesa, M .P . Utrilla, M .E . Rodriguez-Cabezas, N . Chueca, F . Garcia, J . Galvez (Granada, ES)

99 . Newly diagnosed pediatric IBD patients in the last five years . A single center experience M . Rogalidou, K . Katsanos, D . Christodoulou, E . Loutsi, K . Tseka, S . Makariou, M . Tzoufi, E . Tsianos, A . Siamopoulou-Mavridou (Ioannina, GR)

100 . Adipocytokines as differential parameters in inflammatory bowel disease S . Rogoz, I . Silosi, C .A . Silosi, V . Biciusca, M . Cojocaru, M . Cojocaru (Craiova, Bucharest, RO)

101 .* IBD patients show an IgG immune response towards specific intestinal bacteria genera G . Roo-Brand, M . Sadaghian Sadabad, M .C . de Goffau, G . Dijkstra, H .J .M . Harmsen (Groningen, NL)

102 . Demographic characteristics of adult patients with Crohn‘s disease in Split-Dalmatia County, Croatia B . Rosic Despalatovic (Split, HR)

103 . Microbiota profiling in PSC and control patients N .G .M . Rossen, S . Fuentes, K . Boonstra, G . D‘Haens, H .G .H .J . Heilig, E .G . Zoetendal, M . de Vos, C .Y . Ponsioen (Amsterdam, Wageningen, NL)

104 .* Low prevalence of Blastocystis sp . in active ulcerative colitis patients N .G .M . Rossen, A . Bart, N . Verhaar, E . van Nood, R . Kootte, P .F . de Groot, G . D‘Haens, M . Nieuwdorp, C .Y . Ponsioen, T . Gool (Amsterdam, NL)

105 . Perifistular application of adipose-derived mesenchymal stem cells followed by bioluminescence imaging O . Ryska, Z . Serclova, O . Mestak, E . Matouskova, P . Vesely, O . Luksan, I . Mrazova (Prague, CZ)

106 . Accuracy of the Strobel and modified Strobel formulae in pH catheter placement in children: A prospective study to reliably exclude the „out of the box“ diagnosis of gastro-oesophageal reflux disease (GERD) in children with symptoms of possible IBD A . Saha, B . Bhaduri (Maidstone, GB)


19

107 .* Defunctioning ileostomy does not prevent anastomotic leaks after restorative proctocolectomy with ileal pouch-anal anastomosis in patients treated with anti-TNF and steroids S . Sahami, C .J . Buskens, T . Young Fadok, A . de Buck van Overstraeten, A . D‘Hoore, W .A . Bemelman (Amsterdam, NL; Arizona, US; Leuven, BE)

108 . A multicenter evaluation of clinical and surgical risk factors for anastomotic leak after restorative proctocolectomy with ileal pouch-anal anastomosis S . Sahami, C .J . Buskens, R . Lindeboom, T . Young Fadok, A . de Buck van Over-straeten, A . D‘Hoore, W .A . Bemelman (Amsterdam, NL; Arizona, US; Leuven, NL)

109 . Effects of fatty acid amide hydrolase and monoacylglycerol lipase enzyme inhibition on rat visceral pain model Y .S . Sakin, A . Dogrul, F . Ilkaya, M . Seyrek, U .H . Ulas, M . Gulsen, S . Bagci (Ankara, Samsun, TR)

110 .* The lived experience of attending a formal inflammatory bowel disease patient education programme . A phenomenological study M . Sephton, K . Kemp, V . Ridgway (Manchester, Chester, GB)

111 . Transanal surgical treatment of anastomotic complications after restorative proctocolectomy with good functional outcome Z . Serclova, O . Ryska, J . Marvan (Prague, CZ)

112 . Soluble factors and relationship between inflammation and angiogenesis in Crohn‘s disease C .A . Silosi, I . Silosi, M . Cojocaru, V . Biciusca, S . Rogoz, M .V . Boldeanu (Craiova, Bucharest, RO)

113 . Cytokines and metalloproteinases as possible factors implicated in pathogenesis of inflammatory bowel disease (IBD) I . Silosi, C .A . Silosi, V . Biciusca, M . Cojocaru, M .V . Boldeanu, M . Cojocaru, S . Rogoz (Craiova, Bucharest, RO)

114 . Assessment of iron status in patients with inflammatory bowel diseases O . Simonova, T . Boyko, S . Yegorova, O . Sorochan (Dnepropetrovsk, UA)

115 . Activity of the mucosal endothelin-1 degrading peptidases is not diminished in children with inflammatory bowel disease . Is there a role for endothelin-1 in pathogenesis of the disease? R . Snitko, A . Ochocinska, M . Teisseyre, J . Kierkus, R .M . Janas (Warsaw, PL)

116 .* Activation of the bile acid receptor, farnesoid X receptor, does not maintain the epithelial barrier in a human cell line R .A . Speight, C .A . Lamb, J .C . Mansfield, J . Kirby (Newcastle upon Tyne, GB)

117 . Cyclosporine A induced apoptosis causes downregulation of IL-13 in ulcerative colitis S . Steiner, R . Atreya, M .F . Neurath, B . Weigmann (Erlangen, DE)


20

118 . Giant post-inflammatory polyposis in UC – Cut it or cure it? D . Stoyanova, Z . Dunkov, A . Fakirova, A . Mihova (Sofia, BG)

119 . Long-term follow-up results of colonic strictures in patients with Crohn‘s disease: A single-institution experience B . Suvak, Y . Beyazit, E . Kayacetin (Ankara, TR)

120 . Characterization of 41 PSC patients with IBD and long-term follow-up results I . Taskiran, M . Basaranoglu, A . Demirbag, E . Parlak, N . Turhan, M . Yalinkilic, Y . Özin, M . Yüksel, E . Kayacetin, N . Ormeci (Ankara, TR)

121 . Preventative intestine anti-inflammatory effects of a prebiotic obtained from Passiflora edulis peel in the DSS model of mouse colitis M . Toral, C .B . Betim Cazarin, A . Rodriguez-Nogales, F . Algieri, M .P . Utrilla, M .E . Rodriguez-Cabezas, J . Garrido-Mesa, A . Zarzuelo, M .R . Marostica, J . Galvez (Granada, Campinas, ES)

122 . Bone density and bone metabolism in patients with inflammatory bowel disease I . Tuzcuoglu, A . Terzioglu (Manisa, TR)

123 . Infliximab trough levels are lower in patients with acute severe, compared to moderate-severe ulcerative colitis patients B . Ungar, Y . Mazor, H . Yanai, Y . Ron, M . Yavzori, O . Picard, E . Fudim, U . Kopylov, I . Dotan, Y . Chowers, S . Ben-Horin, R . Eliakim (Ramat Gan, Haifa, Tel Aviv, IL)

124 . A pea (Pisum sativum L .) seed extract exhibits intestinal anti-inflammatory effect in the DSS model of mouse colitis P . Utrilla, L .A . Rubio, M . Jesus Peinado, R . Ruiz, A . Clemente, J . Galvez (Granada, ES)

125 . Rectorrhagia in ulcerative colitis and advancer rectal cancers endoscopical method for stopping A .G . Uzunova-Genova, E .N . Nakov, H .G . Uzunov (Sofia, BG)

126 . Endoscopic follow-up of patients with IBD and biological treatment: Achievement and persistence of mucosal healing in patients with clinical remission R . Vadan, L . Gheorghe, M . Diculescu, R . Iacob, I . Bancila, B . Cotruta, N . Zamfirescu, I . Stanel, M . Greere, B . Mateescu, C . Gheorghe (Bucharest, RO)

127 . Thiopurine S-methyltransferase activity in pediatric inflammatory bowel disease A . Vaiopoulou, E . Legaki (Athens, GR)

128 . Differences in gene expression profile in IBD patients treated with 5-ASA and immunosuppressive drugs T . Velikova, I . Karakolev, Z . Spassova, E . Ivanova-Todorova, D . Kyurkchiev, I . Altankova, S . Stanilova (Sofia, Stara Zagora, BG)

129 . Intestine anti-inflammatory effects of oligosaccharides derived from lactulose in the TNBS model of rat colitis T . Vezza, F . Algieri, A . Rodriguez-Nogales, J . Garrido-Mesa, M .P . Utrilla, A . Montilla, A . Cardelle-Cobas, A . Olano, N . Corzo, N . Garrido-Mesa, A . Zarzuelo, M .E . Rodrigues-Cabezas, J . Galvez (Granada, Madrid, ES)


21

130 . Vaccination guidelines: Are we missing the target when injecting our patients? S . Vinnamala, R . Iriarte, S . Gausden, M . McFarlane, J . Pinnel, S . Kathawala, S . Ford, L . Knight, J . Eaden (Coventry, GB)

131 .* Crohn‘s disease (CD) in the elderly – The aged-study on behalf of the LG-IBD A . Viola, N . Manetti, I . Frankovic, R . Monterubbianesi, D . Pugliese, A . Aratri, M . Cappello, S . Saibeni, M . Principi, G . Mocci, F . Castiglione, F . Calella, A . Magarotto, F . Furfaro, G . Scalisi, G . Costantino, L . Samperi, G . Inserra, C . Papi, A . Armuzzi, A . Kohn, R . D‘Inca, V . Annese, F . Manguso, W . Fries (Messina, Florence, Padova, Rome, Palermo, Milan, Bari, Gagliari, Naples, Empoli, San Giovanni Rotondo, Catania, IT)

132 . Ursodeoxycholic acid inhibits colonic mucosal cytokine release and prevents colitis in a mouse model of disease J .B .J . Ward, O .B . Kelly, M . Tambuwala, J . Ni Gabhann, S . Smith, F .E . Murray, C . Jefferies, S .J . Keely (Dublin, IE)

133 . Coated nanoparticles loaded with drug alleviated an induced colitis much more effectively B . Weigmann, H . Ali, C .-M . Lehr, M .F . Neurath (Erlangen, Saarbrücken, DE)

134 . Essential role of the alarmin-like cytokine IL-33 in the control of chronic enteric infections and inflammation S .J . Wirtz, M . Kindermann, T . Mchedlidze, R . Lakra, M .F . Neurath (Erlangen, DE)

135 . Malignancies of the gastrointestinal tract after orthotopic liver transplantation in IKEM, Prague P . Wohl, P . Wohl, M . Benes, P . Drastich, J . Skibova, J . Spicak (Prague, CZ)

136 . Soluble syndecan-1: A novel biomarker in patients with inflammatory bowel disease D . Yablecovitch, A . Stein, M . Simon-Shabat, T . Naftali, G . Gabay, I . Laish, F .M . Konikoff (Kfar Saba, Tel Aviv, IL)

137 . Rs3737240 polymorphism in the extracellular matrix protein 1 (ECM 1) gene in Turkish ulcerative colitis patients E . Yorulmaz, G . Adali, N . Tunali, S . Mungan, H . Yorulmaz, I . Tuncer (Istanbul, TR)

* = Posters of Distinction


22

List of Speakers, Moderators and Scientific OrganizersProf. Dr. Matthieu AllezHôpital Saint-LouisService de Gastroentérologie1 Ave . C . Vellefaux75010 ParisFrancematthieu .allez@gmail .com

Prof. Dr. Gert van AsscheUniversity ZiekenhuisGasthuisbergGastro-entérologieHerestraat 493000 LeuvenBelgiumgert .vanassche@uz .kuleuven .ac .be

Prof. Dr. Laurent BeaugerieHôpital Saint AntoineDepartment of Gastroenterology184, Rue du Faubourg St .-Antoine75571 ParisFrancelaurent .beaugerie@sat .aphp .fr

Prof. Dr. Willem A. BemelmanAcademic Medical CenterMeibergdreef 91105 AZ AmsterdamThe Netherlandsw .a .bemelman@amc .uva .nl

Prof. Dr. Yoram BouhnikHôpital BeaujonUniversité Paris VIIDept . of Gastroenterology100 bd général Leclerc92110 ClichyFranceyoram .bouhnik@gmail .com

Prof. Dr. Franck CarbonnelCHU de BicêtreUniversité Paris SudService d‘Hépatogastroentérologi78 rue du Général Leclerc94275 Le Kremlin BicetreFrancefranck .carbonnel@bct .aphp .fr

Prof. Dr. Jean-Frederic ColombelProfessor of MedicineMount Sinai School of MedicineGastroenterology & HepatologyOne Gustave L . Levy PlaceNew York NY 10029USAjean-frederic .colombel@mssm .edu

Prof. Dr. Jacques CosnesHôpital Saint AntoineService de Gastroentérologie& Nutrition du Prof . Gendre184, Rue du Faubourg St .-Antoine75571 ParisFrancejacques .cosnes@sat .ap-hop-paris .fr

Dr. Silvio DaneseIstituto Clinico Humanitas IRCCSIRCCS in GastroenterologyVia Manzoni, 5620089 RozzanoItalysdanese@hotmail .com

Prof. Dr. Geert D‘HaensAcademic Medical CenterAfdeling MDL C2-112Meibergdreef 91105 AZ AmsterdamThe Netherlandsg .dhaens@amc .uva .nl

Prof. Dr. André D‘HooreUniversity ZiekenhuisGasthuisbergDept . Abdominal SurgeryHerestraat 493000 LeuvenBelgiumandre .dhoore@uz .kuleuven .ac .be


23

Prof. Dr. Axel DignassInnere Medizin IAgaplesion Markus KrankenhausWilhelm-Epstein-Str . 460431 FrankfurtGermany axel .dignass@fdk .info

Dr. Iris DotanTel Aviv Medical CenterIchilov HospitalDepartment of Gastroenterology6, Weizman Street64239 Tel AvivIsraelirisd@tasmc .health .gov .il

Prof. Dr. Laurence EganNational University of IrelandDepartment of Pharmacology& TherapeuticsGalwayIrlandlaurence .egan@nuigalway .ie

Claudio Fiocchi, M.D.Professor of MedicineThe Cleveland Clinic FoundationPathobiology / NC 209500 Euclid AvenueCleveland OH 44195USAfiocchc@ccf .org

Subrata Ghosh, M.D.Professor of Medicine, Microbiology and ImmunologyDepartment of MedicineUniversity of CalgaryCalgaryCanadasubrata .ghosh@albertahealthservices .ca

Dr. Fernando GomollónHospital Clinico UniversitarioLosano BlesaAvenida San Juan Bosco 1550009 ZaragozaSpainfgomollon@telefonica .net

Prof. Dr. Wolfgang KruisInnere MedizinEvang . Krankenhaus KalkBuchforststr . 251103 KölnGermanykruis@evkk .de

Prof. Dr. David LaharieHôpital Haut-Lévêque1 avenue Magellan33604 Pessac CedexFrancedavid .laharie@chu-bordeaux .fr

Prof. Dr. Peter L. LakatosSemmelweis UniversityMedical SchoolI Department of MedicineKoranyi u . 2/a1083 BudapestHungarylakatos .peter_laszlo@ med .semmelweis-univ .hu

Prof. Dr. Edouard LouisC .H .U . Sart TilmanGastroentérologieDomain du Sart Tilman4000 LiègeBelgiumedouard .louis@ulg .ac .be

Dr. Fernando J. Magro DiasHospital de S . JoaoServico de GastroenterologiaAv . Prof . Hernani Monteiro4200-319 PortoPortugalfm@med .up .pt

Prof. Dr. Gerassimos MantzarisEvangelismos HospitalDept . of Gastroenterology45-47, Ipsilantou str .106 75 AthenGreecegjmantzaris@gmail .com


24

Prof. Dr. Philippe MarteauLariboisiere HôpitalService d‘Hepato-Gastroenterologie2, rue Ambroise Paré75010 ParisFrancephilippe .marteau@lrb .aphp .fr

Prof. Dr. Bjorn MoumDepartment of Gastroeneterology, Clinics of MedicineOslo University Hospital Ullevaal& University of OsloGastroenterologisk PoliklinikkBygg 6, 3 etgKirkeveien 1660424 OsloNorwaybjorn .moum@medisin .uio .no

Prof. Dr. Remo PanaccioneUniversity of CalgaryInflammatory Bowel DiseaseClinic, Room 6D30, TRW Building3280 Hospital Drive N .W .Calgary AB T2N 2T9Canadarpanacci@ucalgary .ca

Prof. Dr. Julián PanésHospital Clinico y ProvincialUniversidad de BarcelonaInflammatory Bowel Disease Unitc/ Villarroel no . 17008036 BarcelonaSpainjpanes@clinic .ub .es

Prof. Dr. Laurent Peyrin-BirouletHôpitaux de BraboisC .H .U . de NancyDept . of Hepato-GastroenterologyAllee du Morvan54511 Vandoeuvre-NancyFrancepeyrinbiroulet@gmail .com

Prof. Dr. Jeroen RaesBioinformatics and (eco-)systems biologyDepartment of Structural BiologyVIB - Vrije Universiteit BrusselPleinlaan 21050 BrusselsBelgiumjeroen .raes@vib-vub .be

Prof. Dr. Walter ReinischMedizinische Universität WienGastroenterologie/HepatologieWähringer Gürtel 18-201090 WienAustriawalter .reinisch@meduniwien .ac .at

Prof. Dr. Jonathan M. RhodesDepartment of GastroenterologyFaculty of Health and Life SciencesUniversity of LiverpoolDuncan BuildingDaulby StreetLiverpool L69 3GAGreat Britainrhodesjm@liv .ac .uk

Prof. Dr.Dr. Gerhard RoglerUniversitätsspital ZürichKlinik für Gastroenterologie& HepatologieRämistrasse 1008091 ZürichSwitzerlandgerhard .rogler@usz .ch

William J. Sandborn, M.D.Professor of MedicineUCSD School of MedicineDivision of GastroenterologyBuilding UC 303, Room 2209500 Gilman DriveLa Jolla CA 92093USAwsandborn@ucsd .edu


25

Bruce E. Sands, M.D.Professor of MedicineMount Sinai School of MedicineDepartment of GastroenterologyOne Gustave L . Levy PlaceNew York NY 10029USAbruce .sands@mssm .edu

Prof. Dr. Jürgen SchölmerichKlinikum der Johann WolfgangGoethe-Universität FrankfurtTheodor-Stern-Kai 760596 FrankfurtGermanyjuergen .schoelmerich@kgu .de

Prof. Dr. Stefan SchreiberInnere Medizin IUniversitätsklinikumSchleswig-Holstein, Campus KielArnold-Heller-Straße 3 (Haus 6)24105 KielGermanys .schreiber@mucosa .de

Prof. Dr. Britta SiegmundGastroenterologieCharité UniversitätsmedizinCampus Benjamin Franklin (CBF)Hindenburgdamm 3012203 BerlinGermanybritta .siegmund@charite .de

Dr. Harry SokolGastroenterology and Nutrition DepartmentSaint-Antoine Hospital184, rue du faubourg Saint-Antoine75571 Paris cedex 12Franceharry .sokol@sat .aphp .fr

Prof. Dr. Antonino SpinelliUnità Operativa di Chirurgia Generale IIIIstituto Clinico HumanitasVia A . Manzoni, 5620089 RozzanoItalyantonino .spinelli@humanitas .it

Prof. Dr. Eduard F. StangeInnere Medizin IRobert-Bosch-KrankenhausAuerbachstr . 11070376 StuttgartGermanyeduard .stange@rbk .de

Prof. Dr. Andreas SturmInnere MedizinKrankenhaus WaldfriedeArgentinische Allee 4014163 BerlinGermanya .sturm@waldfriede .de

Prof. Dr. Herbert TilgUniversitätsklinik InnsbruckInnere Medizin IAnichstr . 356020 InnsbruckAustriaherbert .tilg@i-med .ac .at

Theresa Torres Pizarro, M.D.Associate Professor Case Western Reserve University5129 WRB10900 Euclid AveCleveland, OH 44116-7288USAtheresa .pizarro@case .edu

Prof. Dr. C. Janneke van der WoudeErasmus Medical CenterAfd . Gastroenterologie´s-Gravenijkwal 2303015 CE RotterdamThe Netherlandsc .vanderwoude@erasmusmc .nl

Prof. Dr. Andreas M. ZeiherInnere Medizin IIIKlinikum der Johann WolfgangGoethe-Universität FrankfurtTheodor-Stern-Kai 760596 FrankfurtGermanyzeiher@em .uni-frankfurt .de


26

Congress OfficeDuring Falk Symposium 192

Le Palais des Congrès de Paris Telephone: +49 (0)175/7795327 2 Place de la Porte Maillot75853 Paris Cedex 1France

Opening Hours:Thursday, May 29, 2014 16 .00 – 21 .00 hFriday, May 30, 2014 8 .00 – 18 .00 hSaturday, May 31, 2014 8 .30 – 15 .00 h

Congress FeesScientific program of the Falk Symposium 192 e 200,–Students and residents e 100,–

* * * OR * * *

Day ticket e 120,–Students and residents e 60,–

Employees of pharmaceutical companies and their guestsFalk Symposium 192 e 600,-

The congress fees include:- Welcome Evening on May 29, 2014- Refreshments during coffee breaks- Lunch on May 30 and 31, 2014- A copy of the abstract volume

Admission to Scientific EventsFor admission to scientific events your name badge should be clearly visible .

Congress ReportThe official congress report of the Falk Symposium 192 “IBD 2014: Thinking Out of the Box” will be published in English in the second half of 2014 by Karger, Switzerland . Orders for this book at a reduced subscription price of e 35,- can be placed at the Congress Office during the congress in Paris .

Congress Short ReportThe congress short report of the Falk Symposium 192 “IBD 2014: Thinking Out of the Box” will be published by the Falk Foundation e .V . with number FSR 192 in the second half of 2014 .


AirportsOrly, 40 minsRoissy Charles de Gaulle, 40 mins

RailwaysGare du Nord, Gare de l‘Est, 30 minsGare Saint-Lazare, 20 minsGare Montparnasse, 30 minsGare de Lyon & d‘Austerlitz, 30 mins

SubwayLignes / Lines: 1. RER CStation / Stop: Porte Maillot

Directions to Le Palais des Congrès de Paris

Le Palais desCongrès de Paris


General Information:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTelephone: +49(0)761/1514-0Telefax: +49(0)761/1514-359E-mail: [email protected]

P192

e 1-

05/2

014

/1.3

00

Stü

Program

Falk Symposium 192



CME credits 11

Awarded with


Program Awarded - Dr. Falk Pharma€¦ · General Information: FALK FOUNDATION e.V. Leinenweberstr....

Documents

Transcript of Program Awarded - Dr. Falk Pharma€¦ · General Information: FALK FOUNDATION e.V. Leinenweberstr....